• Explore /
  • Poster
  • / Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).

Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).

Abstract Poster

Authors

null

Amit Bahl

Bristol Haematology and Oncology Centre, Bristol, United Kingdom

Amit Bahl , Susan Masson , Zafar I. Malik , Alison J. Birtle , Santhanam Sundar , Robert J. Jones , Nicholas David James , Malcolm David Mason , David Bottomley , Anna Lydon , Simon Chowdhury , James Wylie , Johann Sebastian De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01254279

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 91)

DOI

10.1200/jco.2013.31.6_suppl.91

Abstract #

91

Poster Bd #

F10

Abstract Disclosures

Similar Posters

First Author: Amit Bahl

First Author: Mario A. Eisenberger

First Author: Sergio Bracarda

First Author: Ethan M. Basch